Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466010 | 0.87 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL13785071 | 0.87 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL13785008 | 0.85 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL4340908 | 0.85 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL2545827 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL28515710 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL31582156 | 0.84 | AGTR1 (0.48) | ALDH1A1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL5189041 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL28515610 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 | |
| SCHEMBL3824914 | 0.83 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069341-A1 | INHIBITORS OF HSP90 | CHENE PATRICK | 2009-03-12 | — | — | US | disclosed |
| CN-101027054-A | Inhibitors of HSP90 | NOVARTIS AG (CH) | 2007-08-29 | — | — | CN | disclosed |
| EP-1776110-A1 | INHIBITORS OF HSP90 | Novartis AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006010594-A1 | INHIBITORS OF HSP90 | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069341-A1 | INHIBITORS OF HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2811/4885SMN1; SMN2 3010/4885CYP3A4 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.